There is a better way to predict which patients are at the greatest risk and need immediate intervention for heart disease.
MI-HEART ceramides is a blood test that measures the risk of adverse cardiovascular events and quantifies plasma ceramides, which are clinically shown to be novel biomarkers of unstable atherosclerotic cardiovascular disease.
The MI-HEART blood test has the potential to save patients' lives. With so many confirmed and suspected CAD cases in patients, it can be difficult to know who is at the greatest risk and needs immediate intervention.
MI-HEART ceramides is available in the U.S. exclusively through Mayo Clinic Laboratories and marketed as Hertta in Europe and published as CERT in scientific literature.